Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
Apr 09, 2019 $112.70 $112.87 $112.62 $112.78 704 346
Apr 08, 2019 $112.70 $112.88 $112.55 $112.81 762 599
Apr 05, 2019 $112.82 $113.00 $112.52 $112.57 1 434 993
Apr 04, 2019 $113.06 $113.07 $112.68 $112.72 1 252 265
Apr 03, 2019 $112.84 $113.06 $112.63 $112.90 2 131 754
Apr 02, 2019 $114.00 $114.11 $113.86 $114.01 838 301
Apr 01, 2019 $114.07 $114.11 $113.67 $114.01 1 726 660
Mar 29, 2019 $113.74 $113.93 $113.59 $113.88 1 163 000
Mar 28, 2019 $113.72 $113.74 $113.46 $113.74 1 455 300
Mar 27, 2019 $113.66 $113.66 $113.35 $113.50 1 544 215
Mar 26, 2019 $113.54 $113.76 $113.33 $113.72 871 835
Mar 25, 2019 $113.10 $113.56 $113.10 $113.53 3 500 084
Mar 22, 2019 $113.30 $113.40 $112.97 $113.00 4 039 810
Mar 21, 2019 $113.42 $113.54 $113.25 $113.27 3 635 911
Mar 20, 2019 $113.75 $113.76 $113.50 $113.50 1 525 225
Mar 19, 2019 $113.83 $113.83 $113.55 $113.67 1 434 673
Mar 18, 2019 $113.74 $114.00 $113.68 $113.96 2 232 826
Mar 15, 2019 $113.73 $113.87 $113.50 $113.59 2 488 724
Mar 14, 2019 $113.95 $113.95 $113.57 $113.69 1 934 272
Mar 13, 2019 $113.95 $114.00 $113.82 $113.92 1 472 993
Mar 12, 2019 $113.89 $114.20 $113.78 $113.85 1 291 846
Mar 11, 2019 $113.80 $113.98 $113.73 $113.98 2 766 119
Mar 08, 2019 $113.63 $113.83 $113.55 $113.79 3 379 028
Mar 07, 2019 $113.70 $113.87 $113.54 $113.71 2 899 388
Mar 06, 2019 $113.88 $113.89 $113.31 $113.70 2 243 859
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT